Replasia
Belgian medtech startup developing personalized 3D-printed implants and anatomical analysis software for hip preservation surgery in young adults.
- CEO / Founder
- Peter Mercelis
- Team Size
- 1-10
- Stage
- Early Stage
- Latest Round
- Strategic Investment
- Key Investors
- Materialise; Andy Christensen (medtech entrepreneur); VLAIO (Flanders Innovation & Entrepreneurship — grant); Interreg VA Flanders-Netherlands (PRosPERoS-II project grant)
Technology & Products
Key Products
3D Shelf Implant (personalized 3D-printed titanium implant for adult hip dysplasia); HipStudio (comprehensive 3D hip analysis service for surgical planning including morphological analysis, range of motion, spino-pelvic alignment)
Technological Advantage
Patented 3D Shelf Implant design with guide system; HipStudio software for comprehensive 3D morphological analysis; deep founder expertise from LayerWise (pioneer in medical metal 3D printing); first-in-human clinical trial underway (Aug 2025); strategic partnership with Materialise for regulatory and market access.
Differentiation
Value Proposition
Patient-specific 3D-printed hip implant and analysis software offering a less invasive, joint-preserving alternative to traditional periacetabular osteotomy for young adults with hip dysplasia.
How They Differentiate
Only company combining a personalized 3D-printed extra-articular shelf implant (joint-preserving, outside capsule) with a comprehensive 3D planning/analysis service (HipStudio) specifically for young adult hip dysplasia — a less invasive alternative to periacetabular osteotomy.
Market & Competition
Target Customers
Orthopedic surgeons specializing in hip preservation; hospitals and surgical centers treating young adults with hip dysplasia (DDH) and femoroacetabular impingement (FAI)
Industry Verticals
Orthopedic surgery; Hip preservation; Medical devices
Competitors
Materialise (patient-specific orthopedic solutions, acetabular implants); CytexOrtho (3D-printed/woven hip resurfacing); traditional periacetabular osteotomy (PAO) surgical approach
Growth & Milestones
Major Milestones
2022: Company founded by Peter Mercelis and Tim Van Cleynenbreugel; 2024: VLAIO grant awarded; Aug 2025: First-in-human clinical trial (AthenaTrial) initiated at Anna Hospital, Netherlands; May 2026: Strategic minority investment from Materialise and Andy Christensen; Spring 2026: Selected for Start it Accelerate @KBC cohort